• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道菌群驱动的肝内 B 细胞激活通过先天和适应性信号加重 NASH。

Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling.

机构信息

Department of Integrative Biology & PhysiologyUniversity of Minnesota Medical SchoolMinneapolisMN.

Departments of Immunology and Laboratory Medicine & PathobiologyUniversity of TorontoTorontoONCanada.

出版信息

Hepatology. 2021 Aug;74(2):704-722. doi: 10.1002/hep.31755.

DOI:10.1002/hep.31755
PMID:33609303
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8377092/
Abstract

BACKGROUND AND AIMS

Nonalcoholic steatohepatitis is rapidly becoming the leading cause of liver failure and indication for liver transplantation. Hepatic inflammation is a key feature of NASH but the immune pathways involved in this process are poorly understood. B lymphocytes are cells of the adaptive immune system that are critical regulators of immune responses. However, the role of B cells in the pathogenesis of NASH and the potential mechanisms leading to their activation in the liver are unclear.

APPROACH AND RESULTS

In this study, we report that NASH livers accumulate B cells with elevated pro-inflammatory cytokine secretion and antigen-presentation ability. Single-cell and bulk RNA sequencing of intrahepatic B cells from mice with NASH unveiled a transcriptional landscape that reflects their pro-inflammatory function. Accordingly, B-cell deficiency ameliorated NASH progression, and adoptively transferring B cells from NASH livers recapitulates the disease. Mechanistically, B-cell activation during NASH involves signaling through the innate adaptor myeloid differentiation primary response protein 88 (MyD88) as B cell-specific deletion of MyD88 reduced hepatic T cell-mediated inflammation and fibrosis, but not steatosis. In addition, activation of intrahepatic B cells implicates B cell-receptor signaling, delineating a synergy between innate and adaptive mechanisms of antigen recognition. Furthermore, fecal microbiota transplantation of human NAFLD gut microbiotas into recipient mice promoted the progression of NASH by increasing the accumulation and activation of intrahepatic B cells, suggesting that gut microbial factors drive the pathogenic function of B cells during NASH.

CONCLUSION

Our findings reveal that a gut microbiota-driven activation of intrahepatic B cells leads to hepatic inflammation and fibrosis during the progression of NASH through innate and adaptive immune mechanisms.

摘要

背景与目的

非酒精性脂肪性肝炎(NASH)正迅速成为肝衰竭和肝移植的主要原因。肝炎症是非酒精性脂肪性肝炎(NASH)的一个关键特征,但涉及这一过程的免疫途径仍知之甚少。B 淋巴细胞是适应性免疫系统的细胞,是免疫反应的关键调节者。然而,B 细胞在 NASH 发病机制中的作用以及导致其在肝脏中激活的潜在机制尚不清楚。

方法和结果

在这项研究中,我们报告 NASH 肝脏中积累了具有升高的促炎细胞因子分泌和抗原呈递能力的 B 细胞。NASH 小鼠肝内 B 细胞的单细胞和批量 RNA 测序揭示了反映其促炎功能的转录图谱。相应地,B 细胞缺陷可改善 NASH 进展,而从 NASH 肝脏中过继转移 B 细胞可再现该疾病。在机制上,NASH 期间的 B 细胞激活涉及先天衔接蛋白髓样分化初级反应蛋白 88(MyD88)的信号转导,因为 B 细胞特异性缺失 MyD88 可减少肝 T 细胞介导的炎症和纤维化,但不减少脂肪变性。此外,肝内 B 细胞的激活涉及 B 细胞受体信号,描绘了抗原识别的先天和适应性机制之间的协同作用。此外,将人类非酒精性脂肪性肝病肠道微生物群的粪便微生物群移植到受体小鼠中,通过增加肝内 B 细胞的积累和激活,促进 NASH 的进展,表明肠道微生物因素在 NASH 期间驱动 B 细胞的致病功能。

结论

我们的研究结果表明,肠道微生物群驱动的肝内 B 细胞激活通过先天和适应性免疫机制导致 NASH 进展中的肝炎症和纤维化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/d8b6c834cfbc/HEP-74-704-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/e3561c4fedc4/HEP-74-704-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/59358d72a566/HEP-74-704-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/e5ea34032ce3/HEP-74-704-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/01b92c9102c3/HEP-74-704-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/97350ba2b4d5/HEP-74-704-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/fe921eae9fe7/HEP-74-704-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/d8b6c834cfbc/HEP-74-704-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/e3561c4fedc4/HEP-74-704-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/59358d72a566/HEP-74-704-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/e5ea34032ce3/HEP-74-704-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/01b92c9102c3/HEP-74-704-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/97350ba2b4d5/HEP-74-704-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/fe921eae9fe7/HEP-74-704-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feb3/8456805/d8b6c834cfbc/HEP-74-704-g006.jpg

相似文献

1
Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling.肠道菌群驱动的肝内 B 细胞激活通过先天和适应性信号加重 NASH。
Hepatology. 2021 Aug;74(2):704-722. doi: 10.1002/hep.31755.
2
Blocking integrin αβ-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis.阻断整合素 αβ 介导的 CD4 T 细胞向肠道和肝脏的募集可保护小鼠免受西式饮食诱导的非酒精性脂肪性肝炎。
J Hepatol. 2020 Nov;73(5):1013-1022. doi: 10.1016/j.jhep.2020.05.047. Epub 2020 Jun 12.
3
OX40 Regulates Both Innate and Adaptive Immunity and Promotes Nonalcoholic Steatohepatitis.OX40 调节固有免疫和适应性免疫,并促进非酒精性脂肪性肝炎。
Cell Rep. 2018 Dec 26;25(13):3786-3799.e4. doi: 10.1016/j.celrep.2018.12.006.
4
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.肠 B 细胞在 NASH 微生物群/抗原非依赖性条件下许可代谢性 T 细胞激活,并通过 IgA-FcR 信号传导促进纤维化。
J Hepatol. 2023 Aug;79(2):296-313. doi: 10.1016/j.jhep.2023.04.037. Epub 2023 May 22.
5
B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD).B2 淋巴细胞对氧化应激衍生抗原的反应有助于非酒精性脂肪性肝病(NAFLD)的发展。
Free Radic Biol Med. 2018 Aug 20;124:249-259. doi: 10.1016/j.freeradbiomed.2018.06.015. Epub 2018 Jun 18.
6
Targeting EFHD2 inhibits interferon-γ signaling and ameliorates non-alcoholic steatohepatitis.靶向 EFHD2 抑制干扰素-γ 信号转导并改善非酒精性脂肪性肝炎。
J Hepatol. 2024 Sep;81(3):389-403. doi: 10.1016/j.jhep.2024.04.009. Epub 2024 Apr 25.
7
Adaptive immunity: an emerging player in the progression of NAFLD.适应性免疫:非酒精性脂肪性肝病进展中的新兴参与者。
Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):81-92. doi: 10.1038/s41575-019-0210-2. Epub 2019 Oct 11.
8
Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.肝小异二聚体伴侣的破坏可诱导实验性非酒精性脂肪性肝炎中脂肪变性和炎症的分离。
J Biol Chem. 2020 Jan 24;295(4):994-1008. doi: 10.1074/jbc.RA119.010233. Epub 2019 Dec 12.
9
Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH.高强度运动可改善肝脏炎症和 NASH 的进展。
Mol Metab. 2021 Nov;53:101270. doi: 10.1016/j.molmet.2021.101270. Epub 2021 Jun 10.
10
Qingrequzhuo capsule alleviated methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice through regulating gut microbiota, enhancing gut tight junction and inhibiting the activation of TLR4/NF-κB signaling pathway.清胰浊脂胶囊通过调节肠道微生物群、增强肠道紧密连接和抑制 TLR4/NF-κB 信号通路的激活,缓解蛋氨酸和胆碱缺乏饮食诱导的非酒精性脂肪性肝炎小鼠模型的肝损伤。
Front Endocrinol (Lausanne). 2023 Jan 19;13:1106875. doi: 10.3389/fendo.2022.1106875. eCollection 2022.

引用本文的文献

1
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.代谢功能障碍相关脂肪性肝病(MASLD):肠道微生物群、胰岛素抵抗和糖尿病之间的相互作用
Front Med (Lausanne). 2025 Aug 14;12:1618275. doi: 10.3389/fmed.2025.1618275. eCollection 2025.
2
Dynamic crosstalk between HSCs and liver microenvironment: multicellular interactions in the regulation of liver fibrosis.肝星状细胞与肝脏微环境之间的动态串扰:肝脏纤维化调控中的多细胞相互作用
Front Cell Dev Biol. 2025 Jul 21;13:1635763. doi: 10.3389/fcell.2025.1635763. eCollection 2025.
3
Inflammation in MASLD progression and cancer.
非酒精性脂肪性肝病进展与癌症中的炎症
JHEP Rep. 2025 Apr 2;7(8):101414. doi: 10.1016/j.jhepr.2025.101414. eCollection 2025 Aug.
4
Communication initiated by hepatocytes: The driver of HSC activation and liver fibrosis.肝细胞引发的通讯:肝星状细胞激活和肝纤维化的驱动因素
Hepatol Commun. 2025 Jul 14;9(8). doi: 10.1097/HC9.0000000000000753. eCollection 2025 Aug 1.
5
MASLD development: From molecular pathogenesis toward therapeutic strategies.代谢相关脂肪性肝病的发展:从分子发病机制到治疗策略
Chin Med J (Engl). 2025 Aug 5;138(15):1807-1824. doi: 10.1097/CM9.0000000000003629. Epub 2025 Jul 10.
6
CD47-mediated regulation of glucose and lipid metabolism: implications for the pathogenesis of MASLD.CD47介导的葡萄糖和脂质代谢调节:对代谢相关脂肪性肝病发病机制的影响
Front Endocrinol (Lausanne). 2025 Jun 24;16:1535382. doi: 10.3389/fendo.2025.1535382. eCollection 2025.
7
Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma.代谢功能障碍相关脂肪性肝病及相关肝细胞癌中的肠道微生物群
Nat Rev Gastroenterol Hepatol. 2025 Jul 7. doi: 10.1038/s41575-025-01089-1.
8
Fecal microbiota transplantation from patients into animals to establish human microbiota-associated animal models: a scoping review.将患者的粪便微生物群移植到动物体内以建立人类微生物群相关动物模型:一项范围综述
J Transl Med. 2025 Jun 17;23(1):662. doi: 10.1186/s12967-025-06645-6.
9
Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC.单细胞转录组揭示了从MASH向HCC转变过程中免疫微环境的重编程。
Mol Cancer. 2025 Jun 11;24(1):177. doi: 10.1186/s12943-025-02370-2.
10
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD.非酒精性脂肪性肝炎的免疫致病机制及免疫调节疗法
Cell Mol Immunol. 2025 Jun 10. doi: 10.1038/s41423-025-01307-5.